Evidence map›Paper›PMID 39223375›Full record

ArticleNature cell biology2024

The stress response regulator HSF1 modulates natural killer cell anti-tumour immunity.

Kathryn Hockemeyer, Theodore Sakellaropoulos, Xufeng Chen, Olha Ivashkiv, Maria Sirenko, Hua Zhou, Giovanni Gambi, Elena Battistello, Kleopatra Avrampou, Zhengxi Sun and 10 more

Abstract read
In one paragraph

Article in Nature cell biology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed.

  1. Article
  2. Review
  3. Review
  4. Review
  5. Review
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

20 authors.

Kathryn HockemeyerDepartment of Pathology, NYU Grossman School of Medicine, New York, NY, USA.ORCID http://orcid.org/0000-0002-3942-3129
Theodore SakellaropoulosDepartment of Pathology, NYU Grossman School of Medicine, New York, NY, USA.
Xufeng ChenDepartment of Pathology, NYU Grossman School of Medicine, New York, NY, USA.ORCID http://orcid.org/0000-0001-8325-971X
Olha IvashkivDepartment of Pathology, NYU Grossman School of Medicine, New York, NY, USA.
Maria SirenkoDepartment of Pathology, NYU Grossman School of Medicine, New York, NY, USA.
Hua ZhouApplied Bioinformatics Laboratories, NYU Langone Medical Center, New York, NY, USA.
Giovanni GambiDepartment of Pathology, NYU Grossman School of Medicine, New York, NY, USA.
Elena BattistelloDepartment of Pathology, NYU Grossman School of Medicine, New York, NY, USA.
Kleopatra AvrampouDepartment of Pathology, NYU Grossman School of Medicine, New York, NY, USA.
Zhengxi SunDepartment of Pathology, NYU Grossman School of Medicine, New York, NY, USA.
Maria GuillamotDepartment of Pathology, NYU Grossman School of Medicine, New York, NY, USA.
Luis ChiribogaDepartment of Pathology, NYU Grossman School of Medicine, New York, NY, USA.ORCID http://orcid.org/0000-0002-2028-6873
George JourDepartment of Pathology, NYU Grossman School of Medicine, New York, NY, USA.
Igor DolgalevDepartment of Pathology, NYU Grossman School of Medicine, New York, NY, USA.ORCID http://orcid.org/0000-0003-4451-126X
Kate CorriganDepartment of Pathology, NYU Grossman School of Medicine, New York, NY, USA.
Kamala BhattDepartment of Pathology, NYU Grossman School of Medicine, New York, NY, USA.
Iman OsmanRonald O. Perelman Department of Dermatology, NYU Grossman School of Medicine, New York, NY, USA.
Aristotelis TsirigosDepartment of Pathology, NYU Grossman School of Medicine, New York, NY, USA.ORCID http://orcid.org/0000-0002-7512-8477
Nikos KourtisDepartment of Pathology, NYU Grossman School of Medicine, New York, NY, USA. nikolaos.kourtis@regeneron.com.ORCID http://orcid.org/0000-0003-0228-2219
Iannis AifantisDepartment of Pathology, NYU Grossman School of Medicine, New York, NY, USA. Ioannis.Aifantis@nyulangone.org.ORCID http://orcid.org/0000-0001-6857-1035

Funding

Vaccine FacilityP30CA016087 · NCI · NEW YORK UNIVERSITY SCHOOL OF MEDICINE · PI Richard Lewis Possemato · 1985 to 2026
$83.1M
TRAINING PROGRAM IN MOLECULAR ONCOLOGY &IMMUNOLOGYT32CA009161 · NCI · NEW YORK UNIVERSITY SCHOOL OF MEDICINE · PI CARROLL, WILLIAM L., LEVY, DAVID E · 1985 to 2020
$13.3M
Project 4P50CA225450 · NCI · NEW YORK UNIVERSITY SCHOOL OF MEDICINE · PI KIRCHHOFF, TOMAS · 2019 to 2025
$12.5M
Medical Scientist Research Service AwardT32GM136573 · NIGMS · NEW YORK UNIVERSITY SCHOOL OF MEDICINE · PI SULMAN, ERIK · 2020 to 2024
$6.8M
Dissecting innate immune signaling in pre-leukemia evolutionR01CA271455 · NCI · CINCINNATI CHILDRENS HOSP MED CTR · PI Iannis Aifantis, Daniel Starczynowski · 2022 to 2026
$3.2M
Mechanisms of enhancer regulation in leukemiaR01CA228135 · NCI · NEW YORK UNIVERSITY SCHOOL OF MEDICINE · PI AIFANTIS, IANNIS · 2019 to 2023
$2.5M
Mapping cancer micro-environments for acute leukemiaR01CA202025 · NCI · NEW YORK UNIVERSITY SCHOOL OF MEDICINE · PI AIFANTIS, IANNIS, SCHWAB, SUSAN RUTH · 2016 to 2020
$2.3M
Post-translational control of cancer cell stress response and metastasisR01CA202027 · NCI · NEW YORK UNIVERSITY SCHOOL OF MEDICINE · PI AIFANTIS, IANNIS, HERNANDO, EVA · 2016 to 2020
$2.3M
The role of inflammation in the regulation of immune response in acute myeloid leukemiaR01CA283574 · NCI · NEW YORK UNIVERSITY SCHOOL OF MEDICINE · PI Iannis Aifantis, Ann-Kathrin Eisfeld · 2023 to 2026
$2.3M
Altered Dependencies of Melanoma on Rewired Post-Transcriptional RegulationF30CA232704 · NCI · NEW YORK UNIVERSITY SCHOOL OF MEDICINE · PI HOCKEMEYER, KATHRYN GRACE · 2019 to 2022
$152k
NCI NIH HHS F30 CA232704NCI NIH HHS P30 CA016087NCI NIH HHS P50 CA225450NCI NIH HHS R01 CA202025NCI NIH HHS R01 CA202027NCI NIH HHS R01 CA228135NCI NIH HHS R01 CA271455NCI NIH HHS R01 CA283574NCI NIH HHS T32 CA009161NIGMS NIH HHS T32 GM136573
6 · The paper itself

Abstract

Diverse cellular insults converge on activation of the heat shock factor 1 (HSF1), which regulates the proteotoxic stress response to maintain protein homoeostasis. HSF1 regulates numerous gene programmes beyond the proteotoxic stress response in a cell-type- and context-specific manner to promote malignancy. However, the role(s) of HSF1 in immune populations of the tumour microenvironment remain elusive. Here, we leverage an in vivo model of HSF1 activation and single-cell transcriptomic tumour profiling to show that augmented HSF1 activity in natural killer (NK) cells impairs cytotoxicity, cytokine production and subsequent anti-tumour immunity. Mechanistically, HSF1 directly binds and regulates the expression of key mediators of NK cell effector function. This work demonstrates that HSF1 regulates the immune response under the stress conditions of the tumour microenvironment. These findings have important implications for enhancing the efficacy of adoptive NK cell therapies and for designing combinatorial strategies including modulators of NK cell-mediated tumour killing.

Indexed as

Heat Shock Transcription FactorsKiller Cells, NaturalTumor MicroenvironmentAnimalsCell Line, TumorCytokinesCytotoxicity, ImmunologicFemaleGene Expression Regulation, NeoplasticHumansMiceMice, Inbred C57BLNeoplasmsCytokinesHeat Shock Transcription FactorsHSF1 protein, humanHsf1 protein, mouse

Identifiers

PMID39223375
PMCPMC12312658

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.